NCT06666673View on ClinicalTrials.gov

Effect of Neural Constraints on Movement in Stroke

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

August 23, 2024

Primary Completion Date

June 30, 2029

Study Completion Date

July 31, 2029

Conditions
Stroke
Interventions
DRUG

Tizanidine

Tizanidine (TIZ) (Zanaflex®) is a centrally acting noradrenergic α-2 agonist and a ligand of I3 (non-I1/I2) imidazoline receptors. It is currently indicated for the management of spasticity.

DRUG

Placebo

Administered as control

Trial Locations (1)

60611

RECRUITING

Northwestern University, Dept. of PTHMS 645 N Michigan Ave, Suite 1100, Chicago

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

Northwestern University

OTHER